These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15304171)

  • 41. Intraperitoneal chemotherapy comes of age.
    Cannistra SA
    N Engl J Med; 2006 Jan; 354(1):77-9. PubMed ID: 16394306
    [No Abstract]   [Full Text] [Related]  

  • 42. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
    J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Consensus and new development in epithelial ovarian cancer chemotherapy in 1995].
    Hatae M; Onishi Y; Maeda Y; Nakamura T; Maeda T; Wada T
    Gan To Kagaku Ryoho; 1995 Aug; 22(9):1182-9. PubMed ID: 7661570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
    Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
    J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Confirmation of the "old" standard of care for ovarian cancer and a challenge.
    McGuire WP
    J Natl Cancer Inst; 2000 May; 92(9):674-5. PubMed ID: 10793094
    [No Abstract]   [Full Text] [Related]  

  • 46. Intraperitoneal therapy of ovarian cancer.
    Markman M
    Semin Oncol; 1998 Jun; 25(3):356-60. PubMed ID: 9633848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Update on gynecology].
    Diéras V
    Bull Cancer; 1998 Jan; 85(1):35-6. PubMed ID: 9752343
    [No Abstract]   [Full Text] [Related]  

  • 49. Paclitaxel plus carboplatin in the treatment of ovarian cancer.
    Ozols RF
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Optimal therapeutic strategies in ovarian epithelial cancer in 1997].
    Piccart MJ; Nogaret JM
    Rev Med Brux; 1997 Sep; 18(4):198-203. PubMed ID: 9411642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
    Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
    N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
    Rowan K
    J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
    [No Abstract]   [Full Text] [Related]  

  • 54. Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group.
    Williams SD; Blessing JA; Hatch KD; Homesley HD
    J Clin Oncol; 1991 Nov; 9(11):1950-5. PubMed ID: 1719142
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
    Landrum LM; Hyde J; Mannel RS; McMeekin DS; Moore KN; Walker JL
    Gynecol Oncol; 2011 Sep; 122(3):527-31. PubMed ID: 21664657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First-line chemotherapy for ovarian cancer - the controversy continues.
    Kaye SB
    Br J Cancer; 2002 Oct; 87(8):813-4. PubMed ID: 12373592
    [No Abstract]   [Full Text] [Related]  

  • 57. [Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].
    Meerpohl HG
    Praxis (Bern 1994); 1999 Mar; 88(12):513-8. PubMed ID: 10235026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intraperitoneal chemotherapy and the NCI clinical announcement.
    Trimble EL; Alvarez RD
    Gynecol Oncol; 2006 Nov; 103(2 Suppl 1):S18-9. PubMed ID: 17027073
    [No Abstract]   [Full Text] [Related]  

  • 59. Intraperitoneal chemotherapy for ovarian cancer.
    Ozols RF; Bookman MA; Young RC
    N Engl J Med; 2006 Apr; 354(15):1641-3; author reply 1641-3. PubMed ID: 16611959
    [No Abstract]   [Full Text] [Related]  

  • 60. Intraperitoneal chemotherapy for ovarian cancer: 2009 goals.
    Walker JL
    Gynecol Oncol; 2009 Mar; 112(3):439-40. PubMed ID: 19245944
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.